Fate Therapeutics Inc (NASDAQ: FATE) is -55.61% lower on its value in year-to-date trading and has touched a low of $1.59 and a high of $8.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FATE stock was last observed hovering at around $1.68 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $1.66, the stock is -28.01% and -33.62% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.28 million and changing -1.19% at the moment leaves the stock -57.42% off its SMA200. FATE registered -50.45% loss for a year compared to 6-month loss of -55.38%. The firm has a 50-day simple moving average (SMA 50) of $2.5294 and a 200-day simple moving average (SMA200) of $3.93105.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -19.81% gain in the last 1 month and extending the period to 3 months gives it a -51.88%, and is -17.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.23% over the week and 13.75% over the month.
Fate Therapeutics Inc (FATE) has around 181 employees, a market worth around $189.06M and $13.45M in sales. Profit margin for the company is -1325.43%. Distance from 52-week low is 4.40% and -81.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-39.22%).
with sales reaching $1.57M over the same period.The EPS is expected to grow by 0.38% this year, but quarterly earnings will post -78.52% year-over-year. Quarterly sales are estimated to shrink -6.49% in year-over-year returns.
Fate Therapeutics Inc (FATE) Top Institutional Holders
233.0 institutions hold shares in Fate Therapeutics Inc (FATE), with institutional investors hold 104.52% of the company’s shares. The shares outstanding are 113.88M, and float is at 97.96M with Short Float at 11.58%. Institutions hold 102.25% of the Float.
The top institutional shareholder in the company is REDMILE GROUP, LLC with over 13.17 million shares valued at $43.19 million. The investor’s holdings represent 13.0252% of the FATE Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.57 million shares valued at $34.67 million to account for 10.4544 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 10.12 million shares representing 10.0056% and valued at over $33.18 million, while BOXER CAPITAL, LLC holds 8.1262 of the shares totaling 8.22 million with a market value of $26.95 million.
Fate Therapeutics Inc (FATE) Insider Activity
#####
Fate Therapeutics Inc disclosed in a document filed with the SEC on Aug 06 ’24 that Xu Yuan (Director) sold a total of 633 shares of the company’s common stock. The trade occurred on Aug 06 ’24 and was made at $4.23 per share for $2678.0. Following the transaction, the insider now directly holds 8669.0 shares of the FATE stock.
Still, SEC filings show that on Aug 06 ’24, Xu Yuan (Director) Proposed Sale 633 shares at an average price of $4.23 for $2678.0. The insider now directly holds shares of Fate Therapeutics Inc (FATE).
